All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
HONG KONG – France’s Sanofi SA has informed Hanmi Pharmaceuticals Co. Ltd. of its intention to return all the rights to efpeglenatide, the South Korean company’s diabetes drug candidate.
